[HTML][HTML] Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico
…, V Garcia-Fragoso, RA Riesenberg… - … England Journal of …, 2022 - Mass Medical Soc
Background NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine
that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (…
that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (…
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
…, TK Tran-Johnson, RA Riesenberg… - The British Journal of …, 2011 - cambridge.org
BackgroundThere is a need for a rapid-acting, non-injection, acute treatment for agitation.AimsTo
evaluate inhaled loxapine for acute treatment of agitation in schizophrenia.MethodThis …
evaluate inhaled loxapine for acute treatment of agitation in schizophrenia.MethodThis …
Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo‐controlled clinical trial with inhaled loxapine
J Kwentus, RA Riesenberg, M Marandi… - Bipolar …, 2012 - Wiley Online Library
Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, Spyker DA,
Kehne JH, Cassella JV. Rapid acute treatment of agitation in patients with bipolar I disorder: a …
Kehne JH, Cassella JV. Rapid acute treatment of agitation in patients with bipolar I disorder: a …
[HTML][HTML] Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo …
…, A Khan, SD Atkinson, RR Riesenberg… - …, 2017 - nature.com
The objective of this study was to investigate the efficacy and safety of adjunctive lanicemine
(NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 …
(NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 …
Liraglutide effects in a paediatric (7‐11 y) population with obesity: A randomized, double‐blind, placebo‐controlled, short‐term trial to assess safety, tolerability …
…, PM Hale, HK Hedman, RA Riesenberg - Pediatric …, 2019 - Wiley Online Library
Background Childhood obesity is a major public health concern with limited treatment options.
Objective The aim of this study was to assess safety, tolerability, pharmacokinetics, and …
Objective The aim of this study was to assess safety, tolerability, pharmacokinetics, and …
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled study
…, J Schweiger, A Donnely, RA Riesenberg… - Archives of internal …, 1995 - jamanetwork.com
Background: Alzheimer's disease is characterized by cognitive and behavioral disturbances
that are mediated in part by cholinergic brain deficits. Objective: To evaluate the long-term …
that are mediated in part by cholinergic brain deficits. Objective: To evaluate the long-term …
Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a …
RA Riesenberg, I Baldytcheva, C Datto - Clinical therapeutics, 2012 - Elsevier
BACKGROUND: A human-volunteer study reported lower sedation intensity during escalation
of the extended-release formulation of quetiapine fumarate (quetiapine XR) than the …
of the extended-release formulation of quetiapine fumarate (quetiapine XR) than the …
Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens
DA Spyker, RA Riesenberg… - The Journal of Clinical …, 2015 - Wiley Online Library
This randomized, double‐blind, placebo‐controlled, parallel‐group study was to determine
the pharmacokinetic characteristics, safety, and tolerability of multiple doses of inhaled …
the pharmacokinetic characteristics, safety, and tolerability of multiple doses of inhaled …
Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial
…, R Dominguez, J Ferguson, B Muller, R Riesenberg… - Jama, 1998 - jamanetwork.com
Context.—The serotonin reuptake inhibitors are the treatment of choice for patients with
obsessive-compulsive disorder; however, empirical support for this assertion has been weaker …
obsessive-compulsive disorder; however, empirical support for this assertion has been weaker …
[HTML][HTML] Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age
…, N Kitchin, S Lockhart, R Riesenberg… - … England Journal of …, 2023 - Mass Medical Soc
Background Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are
urgently needed in young children. Methods We conducted a phase 1 dose-finding study and …
urgently needed in young children. Methods We conducted a phase 1 dose-finding study and …